8-氯-4-羟基-2-(三氟甲基)喹啉 | 18706-22-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 8-氯-4-羟基-2-(三氟甲基)喹啉
• 中文别名: 2-三氟甲基-4-羟基-8-氯喹啉；8-氯-4-羟基-2-三氟甲基喹啉
• 英文名称: 8-chloro-2-trifluoromethyl-4-quinolinol
• 英文别名: 8-chloro-2-(trifluoromethyl)-1H-quinolin-4-one
• CAS: 18706-22-4
• 化学式: C₁₀H₅ClF₃NO
• mdl: MFCD12147925
• 分子量: 247.604
• InChiKey: SBVZSZNYPRWWNN-UHFFFAOYSA-N

物化性质

• 熔点：
  138 °C
• 沸点：
  333.9±37.0 °C(Predicted)
• 密度：
  1.541±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  常温常压下稳定，避免接触氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2933499090
• 危险类别：
  IRRITANT
• 安全说明：
  S26,S36/37/39,S37/39

SDS

Name:	8-Chloro-2-(trifluoromethyl)quinolin-4-ol 97% Material Safety Data Sheet
Synonym:	8-Chloro-4-hydroxy-2-(trifluoromethyl)quinolin
CAS:	18706-22-4

Section 1 - Chemical Product MSDS Name:8-Chloro-2-(trifluoromethyl)quinolin-4-ol 97% Material Safety Data Sheet
Synonym:8-Chloro-4-hydroxy-2-(trifluoromethyl)quinolin

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
18706-22-4	8-Chloro-2-(trifluoromethyl)quinolin-4	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 18706-22-4: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 138 - 140 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H5ClF3NO
Molecular Weight: 248

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Reducing agents, strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, carbon dioxide, fluorine, hydrogen fluoride gas.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 18706-22-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
8-Chloro-2-(trifluoromethyl)quinolin-4-ol - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 18706-22-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 18706-22-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 18706-22-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  8-氯-4-羟基-2-(三氟甲基)喹啉 在 四氢吡咯 、 sodium tetrahydroborate 、 锂硼氢 、 四(三苯基膦)钯 、 正丁基锂 、 nickel(II) chloride hexahydrate 、 lithium hydroxide monohydrate 、 甲基磺酰氯 、 二异丙胺 、 N,N-二异丙基乙胺 、 间氯过氧苯甲酸 、 苯甲酸 、 三溴氧磷 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 正己烷 、 二氯甲烷 、 水 、 乙腈 为溶剂， 反应 80.25h， 生成 C₃₅H₄₀ClF₃N₄O₇
  参考文献：
  名称：

  [EN] HCV NS3 PROTEASE INHIBITORS
  [FR] INHIBITEURS DE LA PROTÉASE NS3 DU VHC

  摘要：

  这项发明涉及含有螺环结构基团的丙型肝炎病毒（HCV）NS3蛋白酶抑制剂，以及这类化合物的用途和合成。

  公开号：

  WO2014025736A1
• 作为产物：
  描述：

  邻氯苯胺 、 三氟乙酰乙酸乙酯 在 polyphosphoric acid 作用下， 反应 3.25h， 以65%的产率得到8-氯-4-羟基-2-(三氟甲基)喹啉
  参考文献：
  名称：

  [EN] HCV NS3 PROTEASE INHIBITORS
  [FR] INHIBITEURS DE LA PROTÉASE NS3 DU VHC

  摘要：

  这项发明涉及含有螺环结构基团的丙型肝炎病毒（HCV）NS3蛋白酶抑制剂，以及这类化合物的用途和合成。

  公开号：

  WO2014025736A1

文献信息

• Trifluoromethyl substituted analogs of quinine and quinidine
  申请人：Hoffmann-La Roche Inc.

  公开号：US03953453A1

  公开（公告）日：1976-04-27

  Trifluoromethyl substituted analogs of quinine and quinidine are prepared by reacting a 4-quinolyllithium compound with a 4,5-erythro-5-ethyl-(or vinyl)-quinuclidine-2 .xi.-carboxaldehyde or the corresponding quinuclidine-2 .xi.-carboxylic acid alkyl ester. The end products are useful as antimalarial agents.

  三氟甲基取代的奎宁和奎宁啶的类似物是通过将4-喹诺啉锂化合物与4,5-内消旋-5-乙基（或乙烯基）喹诺啉-2 .xi.-羧醛或相应的喹诺啉-2 .xi.-羧酸烷基酯反应制备的。最终产品可用作抗疟疾药物。
• Proline derivatives and use thereof as drugs
  申请人：Kitajima Hiroshi

  公开号：US20050245538A1

  公开（公告）日：2005-11-03

  The present invention aims at providing compounds having therapeutic effects due to a DPP-IV inhibitory action, and satisfactory as pharmaceutical products. The present inventors have found that derivatives having a substituent introduced into the γ-position of proline represented by the formula (I) wherein each symbol is as defined in the specification, have a potent DPP-IV inhibitory activity, and completed the present invention by increasing the stability.

  本发明旨在提供具有治疗效果的化合物，其作用是通过DPP-IV的抑制作用，并且作为药物产品具有令人满意的效果。本发明人发现，在丙氨酸的γ位上引入取代基的衍生物具有强效的DPP-IV抑制活性，并通过增加稳定性完成了本发明。
• Proline derivatives and the use thereof as drugs
  申请人：——

  公开号：US20040106655A1

  公开（公告）日：2004-06-03

  The present invention aims at providing compounds having therapeutic effects due to a DPP-IV inhibitory action, and satisfactory as pharmaceutical products. The present inventors have found that derivatives having a substituent introduced into the &ggr;-position of proline represented by the formula (I) 1 wherein each symbol is as defined in the specification, have a potent DPP-IV inhibitory activity, and completed the present invention by increasing the stability.

  本发明旨在提供具有治疗作用的化合物，由于DPP-IV抑制作用而具有满意的药物产品。本发明人发现，具有引入取代基的脯氨酸γ-位置的衍生物，其化学式为(I)1，其中每个符号如规范中所定义，具有强效的DPP-IV抑制活性，并通过增加稳定性完成了本发明。
• HCV NS3 PROTEASE INHIBITORS
  申请人：BARA Thomas

  公开号：US20140057836A1

  公开（公告）日：2014-02-27

  The present invention relates to hepatitis C virus (HCV) NS3 protease inhibitors containing a spirocyclic moeity, uses of such compounds, and synthesis of such compounds.

  本发明涉及含有螺环结构的丙肝病毒（HCV）NS3蛋白酶抑制剂，以及这些化合物的用途和合成方法。
• PROLINE DERIVATIVES AND USE THEREOF AS DRUGS
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP1308439B1

  公开（公告）日：2008-10-15